Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

被引：0

作者：

Rizvi, Naiyer A. ^{[1
]}

Gettinger, Scott N. ^{[2
]}

Goldman, Jonathan W. ^{[3
]}

Hellmann, Matthew D. ^{[1
]}

Chow, Laura Q. ^{[4
]}

Juergens, Rosalyn ^{[5
]}

Borghaei, Hossein ^{[6
]}

Brahmer, Julie R. ^{[7
]}

Shen, Yun ^{[8
]}

Harbison, Christopher ^{[8
]}

Nathan, Faith ^{[8
]}

Ready, Neal ^{[9
]}

Antonia, Scott J. ^{[10
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Santa Monica, CA USA

[4] Univ Washington, Div Oncol, Seattle, WA 98195 USA

[5] Juravinski Canc Ctr, Hamilton, ON, Canada

[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[7] Sidney Kimmel Comprehens Canc Ctr John Hopkins, Baltimore, MD USA

[8] Bristol Myers Squibb Co, Princeton, NJ USA

[9] Duke Univ, Med Ctr, Durham, NC USA

[10] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

Nivolumab; PD-L1; Ipilimumab; Immunotherapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL02.05

引用

页码：S176 / S176

页数：1

共 50 条

[1] First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.
Gettinger, Scott N.
Hellmann, Matthew David
Shepherd, Frances A.
Antonia, Scott Joseph
Brahmer, Julie R.
Chow, Laura Quan Man
Goldman, Jonathan Wade
Juergens, Rosalyn A.
Borghaei, Hossein
Ready, Neal
Gerber, David E.
Nathan, Faith Ellen
Shen, Yun
Harbison, Christopher
Rizvi, Naiyer A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
Hellmann, M. D.
Rizvi, N.
Gettinger, S. N.
Goldman, J.
Chow, L. Q.
Juergens, R.
Borghaei, H.
Brahmer, J.
Shen, Y.
Harbison, C. T.
Nathan, F.
Ready, N. E.
Antonia, S. J.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S633
[3] PHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
Zalcman, G.
Rizvi, N. A.
Lena, H.
Wolf, J.
Mazieres, J.
Antonia, S. J.
Minenza, E.
Planchard, D.
Lestini, B. J.
Ramalingam, S. S.
[J]. ANNALS OF ONCOLOGY, 2015, 26
[4] Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
Antonia, S. J.
Gettinger, S.
Goldman, J.
Chow, L. Q.
Juergens, R.
Borghaei, H.
Brahmer, J. R.
Shen, Y.
Harbison, C.
Chen, A. C.
Ready, N. E.
Rizvi, N. A.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S33
[5] A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).
Spigel, David R.
Reckamp, Karen L.
Rizvi, Naiyer A.
Poddubskaya, Elena
West, Howard Jack
Eberhardt, Wilfried Ernst Erich
Baas, Paul
Antonia, Scott Joseph
Pluzanski, Adam
Vokes, Everett E.
Holgado, Esther
Waterhouse, David Michael
Ready, Neal
Gainor, Justin F.
Aren, Osvaldo Rudy
Horn, Leora
Paz-Ares, Luis
Baudelet, Christine
Lestini, Brian Joseph
Brahmer, Julie R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[6] First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
Gettinger, S. N.
Hellmann, M. D.
Shepherd, F. A.
Antonia, S. J.
Brahmer, J.
Chow, L. Q.
Goldman, J.
Juergens, R.
Borghaei, H.
Ready, N. E.
Gerber, D. E.
Nathan, F.
Shen, Y.
Harbison, C. T.
Rizvi, N.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S632
[7] Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
Takuma Imakita
Kohei Fujita
Takanori Ito
Zentaro Saito
Issei Oi
Osamu Kanai
Hiromasa Tachibana
Satoru Sawai
Tadashi Mio
[J]. Discover Oncology, 14
[8] Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
Imakita, Takuma
Fujita, Kohei
Ito, Takanori
Saito, Zentaro
Oi, Issei
Kanai, Osamu
Tachibana, Hiromasa
Sawai, Satoru
Mio, Tadashi
[J]. DISCOVER ONCOLOGY, 2023, 14 (01)
[9] Safety and clinical efficacy of programmed cell death 1 antibodies (PD-1 Ab) in patients with advanced non-small cell lung cancer (NSCLC).
Ksienski, Doran
Wai, Elaine
Croteau, Nicole
Lesperance, Mary
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
[10] Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
Lee, Yong Jun
Lee, Jii Bum
Ha, Sang-Jun
Kim, Hye Ryun
[J]. MOLECULES AND CELLS, 2021, 44 (05) : 363 - 373

← 1 2 3 4 5 →